Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients
NCT01868685 · Novartis Pharmaceuticals · PHASE2 · withdrawn · last registry update 2015-01-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ACVR2B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-10-28Results posted on the registry: Medtronic Spinal and Biologics, a drug against ACVR2B (NCT01415908)
- 2015-10-09Phase 3 first posted: Novartis Pharmaceuticals, Bimagrumab + Placebo (NCT02573467)
- 2015-07-21Phase 3 first posted: BioAlpha Inc., a drug against ACVR2B (NCT02504242)
- 2015-05-29Results posted on the registry: Nobel Biocare, a drug against ACVR2B (NCT00422279)
- 2015-05-13Results posted on the registry: Novartis Pharmaceuticals, BYM338 active drug + Placebo (NCT01433263)
- 2015-01-21Also stopped (terminated): Medtronic Spinal and Biologics, a drug against ACVR2B (NCT01016067)
- 2014-11-04Results posted on the registry: Medtronic Spinal and Biologics, a drug against ACVR2B (NCT01016067)
- 2014-09-26Phase 3 first posted: Novartis Pharmaceuticals, BYM338 (Bimagrumab) (NCT02250443)
- 2014-02-21Results posted on the registry: University of Missouri-Columbia, a drug against ACVR2B (NCT00829621)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision